Trial Profile
Phase I/II Study of EGFR CART Cells for Patients With Metastatic Colorectal Cancer.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-EGFR chimeric antigen receptor T cell therapy-The-Beijing-Pregene-Science-Technology-Company (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 24 May 2017 New trial record
- 23 May 2017 Status changed from not yet recruiting to recruiting.